CTA
KYNB

Carillon Tower Advisers’s Kyntra Bio KYNB Stock Holding History

Carillon Tower Advisers’s Portfolio KYNB Stock Details KYNB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-28,333
Closed -$38.5M – 474
2019
Q1 		$38.5M Hold
28,333
– – 0.27% 135
2018
Q4 		$32.8M Hold
28,333
– – 0.28% 139
2018
Q3 		$43M Hold
28,333
– – 0.31% 125
2018
Q2 		$44.3M Buy
28,333
+4,294
+18% +$5.6M 0.35% 96
2018
Q1 		$27M Hold
24,039
– – 0.21% 166
2017
Q4 		$282K Buy
+24,039
New +$30.1M 3.01% 2

Other funds holding KYNB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Carillon Tower Advisers's KYNB Position: Q2 2019 in Review

Carillon Tower Advisers sold out of Kyntra Bio (KYNB) in Q2 2019, closing a stake of 28,333 shares — an estimated $38.5M sold.

Carillon Tower Advisers first reported a position in KYNB in Q4 2017 and held it in 6 quarters. The position peaked at $44.3M in Q2 2018. 190 funds tracked by Wall St. Rank hold KYNB as of Q2 2019.

  • Carillon Tower Advisers reported no remaining Kyntra Bio position as of Q2 2019 after selling out during the quarter.
  • Carillon Tower Advisers sold 28,333 Kyntra Bio shares in Q2 2019, an estimated $38.5M.
  • Carillon Tower Advisers first reported a position in Kyntra Bio in Q4 2017 and held it in 6 quarters.
  • Carillon Tower Advisers's Kyntra Bio position peaked at $44.3M in Q2 2018.
  • 190 funds tracked by Wall St. Rank held Kyntra Bio as of Q2 2019.

Based on Carillon Tower Advisers's 13F filing for Q2 2019, filed 8 Aug 2019.